Study title: RM2003/00271/00 A double blind placebo controlled, parallel group study to evaluate two dose levels (5mg and 20mg) of sumatriptan nasal spray in the acute treatment of a single migraine attack in adolescent migraineurs (12-17 yrs).
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Nervous System Diseases [C10] | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: SUMATRIPTAN | |||||
ATC code: N02CC01 | |||||
Document link: Sumatriptan-SUM30045-ICHE3.pdf | |||||
Document date: 2011-10-20 | |||||
Study number: SUM30045 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | Y |